Aditxt, Inc. (NASDAQ:ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) and meets all other applicable criteria for continued listing.
Aditxt recently completed a reverse stock split and closed a $20 million public offering. Amro Albanna, co-founder, chairman and CEO of Aditxt, said both events were key to the Company’s successful Nasdaq compliance and continued progress within each of the Company’s programs toward commercialization, which currently include AditxtScore™, Adimune™ and Adivir™.
